Abstract
We report here a two-component proteolysis targeting chimeras (PROTACs) strategy selectively targeting O-GalNAcylated and O-GlcNAcylated proteins for proteasomal degradation, which leads to severe toxicity in human cancer cell lines through perturbation of critical metabolic and signaling pathways governed by glycoproteins. Our approach, termed GlyTAC, leverages metabolic incorporation of easily accessible and cell-permeable peracetylated N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc) analogues bearing an azido group into glycoproteins. In living cells, the azido-modified glycoproteins serve as covalent anchors for the introduction of a thalidomide moiety by strain-promoted azide-alkyne cycloaddition (SPAAC) to recruit the E3 ligase cereblon (CRBN), resulting in stepwise ubiquitination of 'sensitized' proteins and their degradation by the proteasome. We show the efficiency of the system in a series of human cancer cell lines and verify the mechanistic pathway by performing control experiments at each stage of the process. Given the characteristic features of cancer cells, including fast nutrient turnover and overall increase of protein glycosylation, as well as the low cytotoxicity of the individual components, our approach may open a feasible strategy in cancer therapy.
Introduction
Proteolysis Targeting Chimeras (PROTACs) represent a powerful modality in drug discovery, designed to force the degradation of disease-relevant proteins by hijacking the cell's natural ubiquitin-proteasome system. However, traditional PROTACs are often large, bulky molecules because they must simultaneously bind both a target protein and an E3 ubiquitin ligase. This high molecular weight frequently leads to poor aqueous solubility and limited cell permeability, hindering their therapeutic potential.
Furthermore, conventional PROTACs typically target a single specific protein, often overlooking the complexity of proteoforms—proteins modified post-translationally. Glycosylation, specifically O-GlcNAcylation and O-GalNAcylation, is a post-translational modification (PTM) that is fundamentally altered in cancer cells to support rapid growth and survival under stress. The GlyTAC (Glycoprotein-Targeting Chimera) platform addresses these challenges by utilizing a two-component, self-assembling system that targets this broad class of cancer-associated glycoproteins.
The GlyTAC Strategy
To overcome the permeability issues of bulky PROTACs, the GlyTAC system splits the degrader into two small, highly permeable components that assemble only once inside the target cell. The process follows a three-step mechanism:
- Metabolic Labeling: Cells are treated with an azide-modified sugar analog, such as Ac4GalNAz or Ac4GlcNAz. Cancer cells, characterized by high nutrient turnover, readily incorporate these synthetic sugars into their glycoproteins using endogenous metabolic pathways.
- In-Cell Click Chemistry: The labeled cells are then treated with DBCO-thalidomide (DBCO-Thal). The DBCO group undergoes a strain-promoted azide-alkyne cycloaddition (SPAAC)—a rapid, copper-free "click" reaction—with the azide tags on the glycoproteins.
- Targeted Degradation: The resulting thalidomide-tagged glycoproteins recruit the E3 ligase Cereblon (CRBN). This recruitment triggers the ubiquitination of the glycoproteins, marking them for destruction by the 26S proteasome.
Results and Discussion
The efficacy of the GlyTAC system was validated across several human cancer cell lines, including HeLa, HCT116, HepG2, and MCF7. In HeLa cells, pre-treatment with Ac4GalNAz followed by DBCO-Thal resulted in an EC50 of approximately 5 µM for the degrader, leading to significant cell death. Notably, neuroblastoma cells (SH-SY5Y) exhibited the highest susceptibility to this treatment.
Quantitative mass spectrometry-based proteomics confirmed the selectivity of the system. At a 20 µM dose of DBCO-Thal, 433 proteins were significantly downregulated. Approximately 75% of these targets were known O-GlcNAcylated proteins, demonstrating that GlyTAC effectively targets the intended glycoprotein pool rather than causing non-specific proteome collapse.
Mechanistic studies further confirmed that the observed cytotoxicity was dependent on the ubiquitin-proteasome pathway. When researchers chemically inhibited ubiquitination (using TAK-243) or the proteasome (using bortezomib), the GlyTAC-induced cell death was successfully halted. Interestingly, a pre-assembled version of the sugar-thalidomide molecule showed virtually no cytotoxicity when applied to cells, emphasizing that the sequential, in-cell self-assembly is critical for overcoming permeability barriers.
Conclusion
GlyTAC represents a novel approach to targeted protein degradation by hijacking the metabolic greed of cancer cells. By targeting a physiological state (glycosylation) rather than a single protein, the system can induce a systems-level collapse of metabolic and signaling pathways. While future work is needed to refine the dosing window and evaluate efficacy in 3D tumor models and in vivo systems, GlyTAC provides a promising framework for developing next-generation, PTM-selective cancer therapies.
Summary updated